Skip Navigation LinksHome > June 2003 - Volume 98 - Issue 6 > Treatment of Excessive Bleeding in Jehovah's Witness Patient...
Anesthesiology:
Case Reports

Treatment of Excessive Bleeding in Jehovah's Witness Patients after Cardiac Surgery with Recombinant Factor VIIa (NovoSeven®)

Tanaka, Kenichi A. M.D.*; Waly, Amr A. M.D.†; Cooper, William A. M.D.‡; Levy, Jerrold H. M.D.§

Free Access
Article Outline
Collapse Box

Author Information

CARDIAC surgery with cardiopulmonary bypass (CPB) poses serious hemostatic challenges in Jehovah's Witnesses, who refuse blood transfusions on religious grounds. Excessive bleeding (> 2 l) after cardiac surgery is encountered in 5–7% of Jehovah's Witness patients, 1 and necessitates reexploration in 3.6% of cases. 2 Recombinant factor VIIa (rFVIIa, NovoSeven®; Novo Nordisk, Princeton, NJ), produced in baby hamster kidney cell lines and free of human protein, could be an alternative hemostatic agent and is generally acceptable to these patients. It has been used in hemophiliac and nonhemophiliac patients to treat bleeding diatheses in medical and surgical settings. We describe two cases of severe microvascular bleeding during and after mitral valve replacement in Jehovah's Witness patients who were successfully treated with a single dose of rFVIIa.
Back to Top | Article Outline

Case Reports

Case 1
A 74-yr-old, 104-kg woman was scheduled for mitral valve replacement. The patient was a Jehovah's Witness, and her medical history included congestive heart failure due to mitral regurgitation, hypertension, and diabetes mellitus. Baseline hematocrit was 32.6%, and activated clotting time was 137 s. Anesthesia was fentanyl based with isoflurane and vecuronium supplementation. Aprotinin (2 million units) was administered as a loading dose, followed by a 2 million-unit pump prime and 500,000 U/h. The mitral valve was replaced after 126 min of CPB, during which hematocrit was 15–18% and blood salvage (cell saver) and ultrafiltration were performed. The patient was initially separated from CPB, and heparin was reversed with protamine. Subsequently, CPB was urgently reinstituted to repair a tear in the left atriotomy site after administration of 400 U/kg heparin. The patient was weaned from CPB after repair, and protamine was administered. Activated clotting time returned to 134 s, but there was persistent microvascular bleeding from the field. Laboratory studies disclosed the following values: hematocrit, 22%; platelet count, 131 × 109/l; prothrombin time (PT), 30.8 s; and fibrinogen, 116 mg/dl. Thromboelastogram analysis showed a reaction time of 32.5 min and a maximum amplitude of 49 mm. Because bleeding continued, the patient received 45 μg/kg rFVIIa prior to chest closure. Results of the repeat laboratory analysis were as follows: activated clotting time, 122 s; PT, 19 sec; platelet count, 63 × 109/l; and fibrinogen, 117 mg/dl. Thromboelastogram results also improved the reaction time to 19 min and maximum amplitude to 66 mm. Over the course of 4 h, the chest tube drainage totaled 200 ml and hematocrit was 24%. The following day, hematocrit was 19%, 24-h chest drainage was 740 ml, and recombinant erythropoietin was started. On the third day, the hematocrit value decreased to 16% but steadily climbed to 22% by the eighteenth day. On the twentieth postoperative day, the patient was discharged from the intensive care unit after being weaned from prolonged ventilatory support.
Back to Top | Article Outline
Case 2
A human immunodeficiency virus-positive 49-yr-old, 76-kg man was scheduled for mitral valve replacement. He was a Jehovah's Witness, and his medical history included congestive heart failure due to mitral regurgitation, diabetes mellitus, and end-stage renal failure requiring hemodialysis. Baseline laboratory data were as follows: hematocrit, 39.7%; platelet count, 155 × 109/l; PT/aPTT, 17.7/52.9 s; and creatinine level, 9.7 mg/dl. Anesthesia was fentanyl based with isoflurane, pancuronium supplementation. Aprotinin was administered as described in case 1. Immediately after CPB was initiated, a profuse left nasal bleed occurred spontaneously. The epistaxis was not controlled with repeated intranasal doses of 0.25% phenylephrine and 0.1% epinephrine, and a right nasal bleed was noted. Nasal passages were packed with epinephrine-soaked gauzes. The mitral valve was replaced after 199 min of CPB, and the patient was separated from CPB with milrinone, norepinephrine, and vasopressin infusions. Activated clotting time returned to baseline values (146 s) after administration of protamine, and desmopressin acetate (32 μg) was given intravenously. Laboratory results were as follows: hematocrit, 26.5%; platelet count, 82 × 109/l; fibrinogen level, 205 mg/dl; and thromboelastogram maximum amplitude, 59 mm. PT/aPTT (27.1/55.3 s) and thromboelastogram reaction time (14.2 min) were prolonged to approximately twice the normal value. Epistaxis and microvascular bleeding from the surgical wound continued, and rFVIIa (60 μg/kg) was given intravenously prior to the chest closure. After 3 min of rFVIIa therapy, clot formation was noticed at the surgical sites, and epistaxis began to slow. Findings of repeat laboratory analysis were as follows: reaction time, 8 min; PT/aPTT, 16.4/56.9 s; and fibrinogen, 176 mg/dL. Abciximab-modified thromboelastogram also showed improvements after rFVIIa therapy; reaction time shortened from 14.5 min to 8 min, and maximum amplitude increased from 14 mm to 21 mm. Chest tube drainage was 270 ml upon arrival in the intensive care unit, and then decreased to an average of 55 ml/h. By the next day, hematocrit was 28.6% and 24-h chest drainage was 1090 ml. The patient was discharged from the intensive care unit on the fourth postoperative day.
Back to Top | Article Outline

Discussion

We have described two cases where a single dose of rFVIIa (NovoSeven®) was used to improve hemostasis in cardiac surgical patients who refused blood products on religious grounds. There are no human protein or derivatives present during the manufacturing or purification processes of recombinant factor VIIa in baby hamster kidney cells; therefore rFVIIa is an acceptable treatment option for these patients. 3
These two Jehovah's Witness patients provided us with a unique opportunity to examine the effect of rFVIIa in the treatment of CPB-induced coagulopathy without transfusion. We used aprotinin prophylactically in both cases, and desmopressin acetate was administered to improve platelet adhesiveness in a patient with preexisting renal insufficiency (case 2). However, profuse microvascular bleeding continued, secondary to prolonged CPB. When there were no therapeutic options remaining for these patients, rFVIIa was administered and hemostasis improved. High doses of rFVIIa are used to control bleeding episodes in hemophilia A and B patients who have inhibitory antibodies against FVIII or FIX, respectively. 4 In addition, off-label use of rFVIIa has been reported for the treatment of uncontrollable bleeding in trauma, 5 cardiac surgery, 6,7 orthotopic liver transplantation, 8 and prostatectomy. 9 While the optimal effective dose remains to be determined, 90 μg/kg rFVIIa has been accepted as a standard dose. 4 We administered a smaller dose (45–60 μg/kg) of rFVIIa than that suggested for hemophilia because lower doses have been reported to be effective in nonhemophiliac surgical patients.
Fig. 1
Fig. 1
Image Tools
Reduced thrombin generation at the site of injury is not uncommon after CPB. This is because coagulation factors are diluted, and platelets are often defective and deficient. FVIIa plays a critical role in initiating thrombin generation by binding to tissue factor at injury sites. 10 rFVIIa is believed to increase thrombin generation, activate platelets, and stabilize fibrin polymerization (fig. 1). 11,12 Thromboelastogram tracings depicted characteristics of rFVIIa action. Before and after rFVIIa therapy, reaction time was reduced in both native and abciximab-modified thromboelastogram. Suppression of glycoprotein IIb/IIIa abrogates the contribution of platelets to clot formation; therefore, improved thromboelastogram parameters in the presence of abciximab suggest that rFVIIa-mediated clot potentiation is, at least in part, platelet independent. This finding underlies its efficacy in various platelet disorders. 13,14
Dietrich 15 suggests that the mode of action of rFVIIa in cardiac surgical patients is still somewhat controversial. However, clinical experiences with rFVIIa in a large number of patients with hemophilia support its relative safety, 4 though there are a few reported cases of thrombotic episodes. 14,16 Furthermore, bleeding alone is a potentially life-threatening problem where additional therapeutic options are needed.
In summary, we report a refractory surgical wound bleeding and epistaxis in Jehovah's Witness patients following CPB that was successfully managed with a single dose of rFVIIa (45–60 μg/kg). We believe that rFVIIa offers an important therapeutic option in this patient population, although additional studies are needed to prove its safety and efficacy in cardiac surgical patients.
Back to Top | Article Outline

References

1. Testa LD, Tobias JD: Techniques of blood conservation. Part II: Autologous transfusion, intraoperative blood salvage, pharmacologic agents, and cost issues. Am J Anesth 1996; 23: 63–72

2. Mann MC, Votto J, Kambe J, McNamee MJ: Management of the severely anemic patient who refuses transfusion: Lessons learned during the care of a Jehovah's Witness. Ann Int Med 1992; 117: 1042–8

3. Majumdar G, Savidge GF: Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Blood Coag Fibrinol 1993; 4: 1031–3

4. Poon MC: Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001; 8: 312–8

5. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma Infection Crit Care 2001; 51: 431–9

6. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, Musa MO, Al Homaidhi A, Al Fagih M, Andreasen RB: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven(TM)) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coag Fibrinol 2000; 11: S121–7

7. Hendriks HGD, Van der Maaten J, De Wolf J, Waterbolk TW, Slooff MJH, Van der Meer J: An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287–9

8. Hendriks HGD, Meijer K, De Wolf J, Klompmaker IJ, Porte RJ, De Kam PJ, Hagenaars AJM, Melsen T, Slooff MJH, Van Der Meer J: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation 2001; 71: 402–5

9. Friederich PW, Geerdink MGF, Spataro M, Messelink EJ, Henny Ch P, Buller HR, Levi M: The effect of the administration of recombinant activated factor VII (NovoSeven(TM)) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: The PROSE study. Blood Coag Fibrinol 2000; 11: S129–32

10. Ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD: The activation of Factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207–12

11. Hedner U: NovoSeven(TM) as a universal hemostatic agent. Blood Coag Fibrinol 2000; 11: S107–11

12. Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542–547

13. Poon MC, D'Oiron R: Recombinant activated factor VII (NovoSeven(TM)) treatment of platelet-related bleeding disorders. Blood Coag Fibrinol 2000; 11: S55–68

14. D'Oiron R, Menart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Negrier C: Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644–7

15. Dietrich W, Spannagl M, Hendriks HGD, Van der Maaten J, De Wolf J, Der Meer J: Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery (multiple letters). Anesth Analg 2002; 94: 1369–71

16. Peerlinck K, Vermylen J: Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775–6

Cited By:

This article has been cited 56 time(s).

Anz Journal of Surgery
Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding
Kandane-Rathnayake, RK; Isbister, JP; Zatta, AJ; Aoki, NJ; Cameron, P; Phillips, LE
Anz Journal of Surgery, 83(3): 155-160.
10.1111/j.1445-2197.2012.06285.x
CrossRef
British Journal of Anaesthesia
Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post-partum patient
Price, G; Kaplan, J; Skowronski, G
British Journal of Anaesthesia, 93(2): 298-300.
10.1093/bja/aeh196
CrossRef
American Surgeon
Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation
Jabbour, N; Gagandeep, S; Cheng, PA; Boland, B; Mateo, R; Genyk, Y; Selby, R; Zeger, G
American Surgeon, 71(2): 175-179.

Blood
The use of recombinant factor VIIa in the treatment of bleeding disorders
Roberts, HR; Monroe, DM; White, GC
Blood, 104(): 3858-3864.
10.1182/blood-2004-06-2223
CrossRef
American Journal of Hematology
Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient
Veneri, D; Franchini, M
American Journal of Hematology, 79(4): 344-345.
10.1002/ajh.20345
CrossRef
Anesthesia and Analgesia
Small-dose recombinant activated factor VII (NovoSeven (R)) in cardiac surgery
Romagnoli, S; Bevilacqua, S; Gelsomino, S; Pradella, S; Ghilli, L; Rostagno, C; Gensini, GF; Sorbara, C
Anesthesia and Analgesia, 102(5): 1320-1326.
10.1213/01.ane.0000209023.96418.e5
CrossRef
Journal of Cardiothoracic Surgery
Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant
Gandhi, MJ; Pierce, RA; Zhang, L; Moon, MR; Despotis, GJ; Moazami, N
Journal of Cardiothoracic Surgery, 2(): -.
ARTN 32
CrossRef
British Journal of Anaesthesia
Probable right atrial thrombus immediately after recombinant activated factor VII administration
Pang, G; Donaldson, A
British Journal of Anaesthesia, 99(2): 221-225.
10.1093/bja/aem099
CrossRef
Platelets
The interaction of factor VIIa with rehydrated, lyophilized platelets
Fischer, TH; Wolberg, AS; Bode, AP; Nichols, TC
Platelets, 19(3): 182-191.
10.1080/09537100701493794
CrossRef
American Journal of Critical Care
Successful use of recombinant factor VIIa for treatment of severe postpartum hemorrhage
Hamaekers, AEW; van Mook, WNKA; Offermans, JPM; Marcus, MAE
American Journal of Critical Care, 15(4): 399-401.

Annals of Thoracic Surgery
Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery
Halkos, ME; Levy, JH; Chen, E; Reddy, S; Lattouf, OM; Guyton, RA; Song, HK
Annals of Thoracic Surgery, 79(4): 1303-1306.
10.1016/j.athoracsur.2004.09.034
CrossRef
Annals of Hematology
Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome
Ozelo, MC; Svirin, P; Larina, L
Annals of Hematology, 84(): 816-822.
10.1007/s00277-005-1080-y
CrossRef
Annales Francaises D Anesthesie Et De Reanimation
Recombinant activated factor VII to control bleeding in cardiovascular surgery: need of efficacy and safety validation
Blanloeil, Y; Rigal, JC; Bastien, O; Carteau, JP; Toussaint-Hacquard, M; Lecompte, T
Annales Francaises D Anesthesie Et De Reanimation, 25(1): 2-5.
10.1016/j.annfar.2005.09.005
CrossRef
Anaesthesia
Beriplex P/N: an alternative to fresh frozen plasma in severe haemorrhage
Bhardwaj, M; Bunsell, R
Anaesthesia, 62(8): 832-834.
10.1111/j.1365-2044.2007.05134.x
CrossRef
Injury-International Journal of the Care of the Injured
Low-dose recombinant factor VIIa for trauma patients with coagulopathy
Stein, DM; Dutton, RP; Hess, JR; Scalea, TM
Injury-International Journal of the Care of the Injured, 39(9): 1054-1061.
10.1016/j.injury.2008.03.032
CrossRef
Anaesthesia and Intensive Care
The use of recombinant activated factor VII for refractory bleeding post complex cardiothoracic surgery
Walsham, J; Fraser, JF; Mullany, D; Ziegenfus, M; Chinthamuneedi, M; Dunning, J; Tesar, P
Anaesthesia and Intensive Care, 34(1): 13-20.

Annals of Thoracic Surgery
Recombinant activated factor VII in cardiac surgery: A systematic review
Warren, O; Mandal, K; Hadjianastassiou, V; Knowlton, L; Panesar, S; John, K; Darzi, A; Athanasiou, T
Annals of Thoracic Surgery, 83(2): 707-714.
10.1016/j.athoracsur.2006.10.033
CrossRef
Anaesthesia
Recombinant activated factor VII and the anaesthetist
Welsby, IJ; Monroe, DM; Lawson, JH; Hoffmann, M
Anaesthesia, 60(): 1203-1212.
10.1111/j.1365-2044.2005.04376.x
CrossRef
American Journal of Otolaryngology
Management of Jehovah's Witnesses in otolaryngology, head and neck surgery
Adolola, OA; Ahmed, I; Fenton, JE
American Journal of Otolaryngology, 29(4): 270-278.
10.1016/j.amjoto.2007.08.006
CrossRef
Transfusion
Hemostatic agents
Levy, JH
Transfusion, 44(): 58S-62S.

Chest
Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass
DiDomenico, RJ; Massad, MG; Kpodonu, J; Navarro, RA; Geha, AS
Chest, 127(5): 1828-1835.

Injury-International Journal of the Care of the Injured
The use of factor VIIa in haemorrhagic shock and intracerebral bleeding
Dutton, RP; Stein, DM
Injury-International Journal of the Care of the Injured, 37(): 1172-1177.
10.1016/j.injury.2006.09.001
CrossRef
Anesthesia and Analgesia
What is blood and what is not? Caring for the Jehovah's Witness patient undergoing cardiac surgery
Sniecinski, R; Levy, JH
Anesthesia and Analgesia, 104(4): 753-754.
10.1213/01.ane.0000255644.73211.f2
CrossRef
Hematology Journal
Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia
Virchis, A; Hughes, C; Berney, S
Hematology Journal, 5(3): 281-282.

Thrombosis and Haemostasis
Recombinant factor VIIa - An update on its clinical use
Franchini, M; Zaffanello, M; Veneri, D
Thrombosis and Haemostasis, 93(6): 1027-1035.
10.1160/TH05-01-0032
CrossRef
Anesthesia and Analgesia
Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: Management of two cases using fractionated components and factor VIIa
Sniecinski, RM; Chen, EP; Levy, JH; Szlam, F; Tanaka, KA
Anesthesia and Analgesia, 104(4): 763-765.
10.1213/01.ane.0000250913.45299.f3
CrossRef
Anesthesia and Analgesia
Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient wfth heparin-induced thrombocytopenia
Stratmann, G; deSilva, AM; Tseng, EE; Hambleton, J; Balea, M; Romo, AJ; Mann, MJ; Achorn, NL; Moskalik, WF; Hoopes, CW
Anesthesia and Analgesia, 98(6): 1635-1639.

Anesthesia and Analgesia
Improved clot formation by combined administration of activated factor VII (NovoSeven (R)) and fibrinogen (Haemocomplettan (R) P)
Tanaka, KA; Taketomi, T; Szlam, F; Calatzis, A; Levy, JH
Anesthesia and Analgesia, 106(3): 732-738.
10.1213/ane.0b013e318163fc76
CrossRef
American Surgeon
A Jehovahs witness with complex abdominal trauma and coagulopathy: Use of factor VII and a review of the literature
Haan, J; Scalea, T
American Surgeon, 71(5): 414-415.

Surgical Clinics of North America
Special lessons learned from Iraq
Sebesta, J
Surgical Clinics of North America, 86(3): 711-+.
10.1016/j.suc.2006.03.002
CrossRef
Annals of Thoracic Surgery
Prophylactic Use of Factor IX Concentrate in a Jehovah's Witness Patient
Bolliger, D; Sreeram, G; Duncan, A; Molinaro, RJ; Szlam, F; Chen, EP; Tanaka, KA
Annals of Thoracic Surgery, 88(5): 1666-1668.
10.1016/j.athoracsur.2009.03.095
CrossRef
Critical Care
Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma
Pusateri, AE; Park, MS
Critical Care, 9(): 15-24.
10.1186/cc3781
CrossRef
European Journal of Anaesthesiology
Risks associated with bleeding and transfusion: rationale for the optimal management of bleeding after cardiac surgery
Despotis, G; Renna, M; Eby, C
European Journal of Anaesthesiology, 24(): 15-36.
10.1017/S0265021507000580
CrossRef
Critical Care Clinics
Emerging off-label uses for recombinant activated factor VII: Grading the evidence
Enomoto, TM; Thorborg, P
Critical Care Clinics, 21(3): 611-+.
10.1016/j.ccc.2005.04.001
CrossRef
Anaesthesia and Intensive Care
Use of recombinant activated factor VII after axillofemoral bypass grafting
Cheng, CAY; Ho, AMH
Anaesthesia and Intensive Care, 34(3): 375-378.

Medizinische Klinik
Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group
Dempfle, CE; Gulba, D; Kirchmaier, CM; Klamroth, R; Korte, W; Lorenz, R; Peck-Radosavljevic, M; Veldman, A; Zotz, RB
Medizinische Klinik, 102(1): 70-81.
10.1007/s00063-007-1012-9
CrossRef
Acta Obstetricia Et Gynecologica Scandinavica
Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use
Sobieszczyk, S; Breborowicz, GH; Platicanov, V; Tanchev, S; Kessler, CM
Acta Obstetricia Et Gynecologica Scandinavica, 85(): 1239-1247.
10.1080/00016340600855839
CrossRef
Annals of Thoracic Surgery
Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery
Raivio, P; Suojaranta-Ylinen, R; Kuitunen, AH
Annals of Thoracic Surgery, 80(1): 66-71.
10.1016/j.athoracsur.2005.02.044
CrossRef
American Journal of Health-System Pharmacy
Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation
Levy, JH
American Journal of Health-System Pharmacy, 62(): S15-S19.
10.2146/ajhp050303
CrossRef
Clinical and Applied Thrombosis-Hemostasis
Control of bleeding caused by thrombocytopenia associated with Hematologic malignancy: An audit of the clinical use of recombinant activated factor VII
Brenner, B; Hoffman, R; Balashov, D; Shutluko, E; Culic, S; Nizamoutdinova, E
Clinical and Applied Thrombosis-Hemostasis, 11(4): 401-410.

International Journal of Hematology
Recombinant factor VIIa: A review on its clinical use
Franchini, M
International Journal of Hematology, 83(2): 126-138.
10.1532/IJH97.E0517
CrossRef
Critical Care Clinics
Critical care clotting catastrophies
DeLoughery, TG
Critical Care Clinics, 21(3): 531-+.
10.1016/j.ccc.2005.05.003
CrossRef
Seminars in Hematology
Massive transfusion coagulopathy
Levy, JH
Seminars in Hematology, 43(1): S59-S63.
10.1053/j.seminhematol.2005.11.019
CrossRef
Anesthesia and Analgesia
Novel concepts in treatment and prevention of bleeding
Levy, JH
Anesthesia and Analgesia, (): 43-47.

Critical Care Clinics
Bleeding in cardiac surgery: Its prevention and treatment - an evidence-based review
Whitlock, R; Crowther, MA; Ng, HJ
Critical Care Clinics, 21(3): 589-+.
10.1016/j.ccc.2005.04.003
CrossRef
Transfusion
A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery
Despotis, G; Eby, C; Lublin, DM
Transfusion, 48(1): 2S-30S.
10.1111/j.1537-2995.2007.01573.x
CrossRef
Journal of the Formosan Medical Association
Successful treatment of intractable hemothorax with recombinant factor VIIa in a nonhemophilic patient
Wei, YF; Ho, CC; Lin, MT; Yuan, A; Yu, CJ
Journal of the Formosan Medical Association, 105(9): 765-769.

European Journal of Cardio-Thoracic Surgery
Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven (R)): a propensity score analysis
Gelsomino, S; Lorusso, R; Romagnoli, S; Bevilacqua, S; De Cicco, G; Bille, G; Stefano, P; Gensini, GF
European Journal of Cardio-Thoracic Surgery, 33(1): 64-71.
10.1016/j.ejcts.2007.10.004
CrossRef
Current Drug Targets
Uncontrolled Bleeding in Surgical Patients: The Role of Recombinant Activated Factor VIIa
Phillips, LE; Zatta, AJ; Schembri, NL; Noone, AK; Isbister, J
Current Drug Targets, 10(8): 744-770.

Anesthesiology
Current Concepts of Hemostasis: Implications for Therapy
Roberts, HR; Monroe, DM; Escobar, MA
Anesthesiology, 100(3): 722-730.

PDF (2293)
Anesthesiology
Deep Vein Thrombosis after Recombinant Factor VIIa Infusion to Control Severe Recurrent Postoperative Bleeding
Pépion, C; Becq, M; Jacob, L
Anesthesiology, 104(4): 892-893.

PDF (292)
Blood Coagulation & Fibrinolysis
Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients
Brandsborg, S; Sørensen, B; Poulsen, LH; Ingerslev, J
Blood Coagulation & Fibrinolysis, 17(4): 241-249.
10.1097/01.mbc.0000224842.25592.8a
PDF (254) | CrossRef
Blood Coagulation & Fibrinolysis
Prophylaxis with recombinant-activated factor VII (rFVIIa) for minimally invasive surgery in a patient with congenital factor VII deficiency: a case report with a single-low dose of rFVIIa
Yilmaz, AA; Yalcin, S; Serdaroglu, H; Sonmezer, M; Uysalel, A
Blood Coagulation & Fibrinolysis, 19(7): 693-695.
10.1097/MBC.0b013e3282f544ff
PDF (71) | CrossRef
Current Opinion in Hematology
Recombinant activated factor VII for non-hemophiliac bleeding patients
Uhlmann, EJ; Eby, CS
Current Opinion in Hematology, 11(3): 198-204.

PDF (86)
Journal of Trauma and Acute Care Surgery
A Review of Recombinant Factor VII for Refractory Bleeding in Nonhemophilic Trauma Patients
Barletta, JF; Ahrens, CL; Tyburski, JG; Wilson, RF
Journal of Trauma and Acute Care Surgery, 58(3): 646-651.

PDF (235)
Journal of Trauma and Acute Care Surgery
“Low-Dose” Recombinant Activated Factor VII Results in Less Blood and Blood Product Use in Traumatic Hemorrhage
Harrison, TD; Laskosky, J; Jazaeri, O; Pasquale, MD; Cipolle, M
Journal of Trauma and Acute Care Surgery, 59(1): 150-154.

PDF (450)
Back to Top | Article Outline

© 2003 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Images

Share